NCT04911751View on ClinicalTrials.gov

A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

November 8, 2021

Primary Completion Date

November 8, 2023

Study Completion Date

October 7, 2024

Conditions
Psoriatic Plaque
Interventions
DRUG

KBL697

1 capsule BID of KBL697 or Placebo

DRUG

KBL697

5 capsules BID of KBL697 or Placebo

Trial Locations (10)

2145

Westmead Hospital, Westmead

2217

Premier Specialist, Kogarah

3002

Sinclair Dermatology, East Melbourne

4102

Veracity Clinical Trials Ltd, Woolloongabba

33012

Indago Research and Health Center, Hialeah

33122

Revival Research Institute, Doral

35205

Total Skin and Beauty Dermatology Center, Birmingham

70809

Louisiana Dermatology Associates - Dermatology, Baton Rouge

90404

Clinical Science Institute, Santa Monica

92701

Southern California Dermatology, Inc, Santa Ana

Sponsors

Lead Sponsor

KoBioLabs
All Listed Sponsors
lead

KoBioLabs

INDUSTRY

NCT04911751 - A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis | Biotech Hunter | Biotech Hunter